MDSpire - Summary
From the Journals
Clinical Guidelines

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

Share

The treatment landscape for myelofibrosis (MF) is evolving with emerging therapies beyond traditional JAK inhibitors like ruxolitinib. Recent studies presented at the 2025 ASH Annual Meeting highlight the benefits of combining ruxolitinib with pelabresib and its impact on disease trajectory. Long-term data from the MANIFEST-2 trial indicates significant improvements in spleen volume reduction and comparable safety profiles. The RESTORE trial shows elritercept effectively manages anemia in MF patients, emphasizing the need for novel therapies. Furthermore, real-world studies reaffirm the long-term feasibility of ruxolitinib, indicating potential improvements in transfusion dependency. Despite advancements, stem cell transplant remains crucial for eligible high-risk patients, offering a curative approach.

Original Source(s)

ASH 2025: Myelofibrosis Roundup

  • by Caroline Helwick

  • March 24, 2026

Related Content

Dynamic, Accessible Risk Stratification Tool Created for Smoldering Multiple Myeloma

Researchers have developed a dynamic risk stratification tool for patients with smoldering multiple myeloma to predict their chance of progression to active multiple myeloma. The tool, called Precurso...

ASH 2025: Myelofibrosis Roundup

For myelofibrosis, the treatment landscape is poised for change as new targets have emerged, and treatments are evolving beyond the standard Janus kinase (JAK) inhibitors. Novel therapies are being pa...

POEMS Syndrome: Diagnostic Clues From Neuropathy to Bone Marrow Findings

POEMS syndrome is a poorly understood and complex paraneoplastic plasma cell disorder characterized by peripheral neuropathy and multisystem involvement, including organomegaly, endocrinopathy, monocl...